Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory MelanomaBusiness Wire • 05/29/26
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast CancerBusiness Wire • 05/28/26
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing TechnologyBusiness Wire • 05/26/26
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in OncologyBusiness Wire • 05/21/26
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the WorldBusiness Wire • 05/21/26
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer StudyZacks Investment Research • 05/20/26
EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients EnrolledBusiness Wire • 05/20/26
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder CancerZacks Investment Research • 05/18/26
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)Business Wire • 05/15/26
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 05/08/26
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLTBusiness Wire • 04/22/26
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell LymphomaBusiness Wire • 04/13/26